Inipharm is a Frazier-founded company focused on discovering and developing therapies for severe liver diseases. The company is advancing a pipeline of small-molecule therapies that target the activity of HSD17B13, which is a genetically validated target in a range of liver diseases (alcoholic, non-alcoholic, viral, and genetic). Inipharm is led by Frazier Entrepreneur-in-Residence Brian Farmer, who is co-founder of the company and serves as its Chief Executive Officer.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.11.2020 | Series A | $35M | - |
Mentions in press and media 6
| Date | Title | Description |
| 12.11.2020 | Inipharm Pulls In $35M Series A Financing |
SEATTLE, WA, Inipharm today announced the close of a $35 million Series A financing round.
>> Click here for more funding data on Inipharm
>> To export Inipharm funding data to PDF and Excel, click here
Founded in 2018, t... |
| 11.11.2020 | Inipharm raises $35M to combat liver diseases with a genetics approach
W h i t e p a p e r
Weighing the Costs: | Liver diseases, including fatty liver disease, cirrhosis and various rare diseases, have differing causes, from viruses, to drugs, to alcohol, to genetics. However, many of these diseases share effects, including inflammation and fibrosis, ... |
| 11.11.2020 | Inipharm raises $35M to combat liver diseases with a genetics approach | Liver diseases, including fatty liver disease, cirrhosis and various rare diseases, have differing causes, from viruses, to drugs, to alcohol, to genetics. However, many of these diseases share effects, including inflammation and fibrosis, ... |
| 11.11.2020 | Biopharma startup Inipharm raises $35M in Series A funding | - |
| 11.11.2020 | Inipharm Raises $35M in Series A Funding | Inipharm, a Seattle and San Diego-based biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, closed a $35m Series A financing round.
Backers included 5AM Ventures and Wu Capital which joined e... |
| 11.11.2020 | Small biotech Inipharm lands $35M to take new NASH approach, diverging from RNAi competitors | A year after Cirius Therapeutics’ lead NASH drug flopped in a large Phase IIb trial, the biotech’s chief business and financial officer Brian Farmer is leading another stab at the Holy Grail of liver disease through the sma... |
Reviews 0
